326 related articles for article (PubMed ID: 16638874)
1. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
[TBL] [Abstract][Full Text] [Related]
2. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
3. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
4. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
5. Transgenic Polyoma middle-T mice model premalignant mammary disease.
Maglione JE; Moghanaki D; Young LJ; Manner CK; Ellies LG; Joseph SO; Nicholson B; Cardiff RD; MacLeod CL
Cancer Res; 2001 Nov; 61(22):8298-305. PubMed ID: 11719463
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.
Liu M; Howes A; Lesperance J; Stallcup WB; Hauser CA; Kadoya K; Oshima RG; Abraham RT
Cancer Res; 2005 Jun; 65(12):5325-36. PubMed ID: 15958580
[TBL] [Abstract][Full Text] [Related]
7. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
Torres-Arzayus MI; Yuan J; DellaGatta JL; Lane H; Kung AL; Brown M
Cancer Res; 2006 Dec; 66(23):11381-8. PubMed ID: 17145884
[TBL] [Abstract][Full Text] [Related]
8. Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.
Bon G; Folgiero V; Bossi G; Felicioni L; Marchetti A; Sacchi A; Falcioni R
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3280-7. PubMed ID: 16740748
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
Nozawa H; Watanabe T; Nagawa H
Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
[TBL] [Abstract][Full Text] [Related]
11. Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression.
Huh JI; Calvo A; Charles R; Green JE
Cancer Res; 2006 Apr; 66(7):3495-503. PubMed ID: 16585173
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation.
Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O
Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F
Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ.
Namba R; Maglione JE; Young LJ; Borowsky AD; Cardiff RD; MacLeod CL; Gregg JP
Mol Cancer Res; 2004 Aug; 2(8):453-63. PubMed ID: 15328372
[TBL] [Abstract][Full Text] [Related]
16. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
17. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
18. Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice.
Zhang H; Kuang SQ; Liao L; Zhou S; Xu J
Cancer Res; 2004 Oct; 64(19):7169-77. PubMed ID: 15466215
[TBL] [Abstract][Full Text] [Related]
19. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model.
Wu Q; Kiguchi K; Kawamoto T; Ajiki T; Traag J; Carbajal S; Ruffino L; Thames H; Wistuba I; Thomas M; Vasquez KM; DiGiovanni J
Cancer Res; 2007 Apr; 67(8):3794-800. PubMed ID: 17440093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
